Christopher Po, MD
Nephrology · Loris, SCNPI 1679665608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,806, 6.2 times the $291 reported in 2019.
Across 216 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$559
- Bayer$480
- AstraZeneca$448
- Calliditas Therapeutics US Inc.$431
- Otsuka America Pharmaceutical, Inc.$422
- Amgen$267
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,61299%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 25 | $559 |
| Bayer | 29 | $480 |
| AstraZeneca | 25 | $448 |
| Calliditas Therapeutics US Inc. | 14 | $431 |
| Otsuka America Pharmaceutical, Inc. | 18 | $422 |
| Amgen | 17 | $267 |
| Novartis | 12 | $234 |
| GSK | 6 | $187 |
| ANI Pharmaceuticals, Inc. | 9 | $180 |
| Lilly USA, LLC | 4 | $157 |
| Travere Therapeutics, Inc. | 10 | $151 |
| Ardelyx, Inc. | 6 | $129 |
| Phathom Pharmaceuticals, Inc. | 4 | $114 |
| Idorsia Pharmaceuticals US Inc | 1 | $111 |
| Pfizer | 1 | $106 |
| AbbVie | 5 | $87 |
| Fresenius USA Marketing, Inc. | 5 | $84 |
| Exact Sciences | 4 | $69 |
| Boehringer Ingelheim | 3 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $68 |
| Novo Nordisk | 3 | $66 |
| Vifor Pharma, Inc. | 2 | $40 |
| Corcept Therapeutics | 2 | $39 |
| Dexcom, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Phadia US Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Gilead | 1 | $15 |
| Medtronic | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,651 in reported general payments places this provider in the 70th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 19 | $991,399 |
| XphozahTenapanor Hcl | 24 | $123,955 |
| FarxigaDapagliflozin Propanediol | 129 | $92,545 |
| JardianceEmpagliflozin | 112 | $73,547 |
| EliquisApixaban | 88 | $39,781 |
| OzempicSemaglutide | 29 | $31,371 |
| KerendiaFinerenone | 26 | $26,599 |
| FosrenolLanthanum Carbonate | 15 | $24,400 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,974 |
| JanuviaSitagliptin Phosphate | 23 | $10,432 |
| Sevelamer Carbonate | 39 | $6,214 |
| LumiganBimatoprost | 15 | $4,065 |
| Calcium Acetate | 56 | $3,689 |
| Potassium Chloride | 53 | $2,644 |
| Atorvastatin Calcium | 141 | $2,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $559 | $991,39919 claims |
| AstraZenecaFarxiga | $448 | $92,545129 claims |
| Boehringer IngelheimJardiance | $68 | $73,547112 claims |
| PfizerEliquis | $106 | $39,78188 claims |
| Novo NordiskOzempic | $66 | $31,37129 claims |
| BayerKerendia | $480 | $26,59926 claims |
| GSKTrelegy Ellipta | $187 | $11,97415 claims |
| AbbVieLumigan | $87 | $4,06515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Loris
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
- Charles BunkeCharleston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.